18 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
33
Selective Degradation of TEADs by a PROTAC Molecule Exhibited Robust Anticancer Efficacy In Vitro and In Vivo.

Shanghai Institute of Materia Medica
24
Discovery of reversible and covalent TEAD 1 selective inhibitors MSC-1254 and MSC-5046 based on one scaffold.

Cancer Research Horizons
10
Fragment-to-Lead Medicinal Chemistry Publications in 2022.

Astex Pharmaceuticals
62
Modulators for palmitoylation of proteins and small molecules.

Hebei University
6
Novel Indazole Compounds as TEAD Inhibitors for Treating Cancer.

Smith, Gambrell & Russell
6
Novel Compounds as TEAD Inhibitors for Treating Cancer.

Smith, Gambrell & Russell
37
A chemical perspective on the modulation of TEAD transcriptional activities: Recent progress, challenges, and opportunities.

Shanghai Institute of Materia Medica
30
Chloroacetamide fragment library screening identifies new scaffolds for covalent inhibition of the TEAD·YAP1 interaction.

Indiana University School of Medicine 635 Barnhill Drive
8
Small-Molecule Cyanamide Pan-TEAD·YAP1 Covalent Antagonists.

Indiana University
2
Optimization of TEAD P-Site Binding Fragment Hit into In Vivo Active Lead

Merck Healthcare
37
Discovery of Covalent Inhibitors Targeting the Transcriptional Enhanced Associate Domain Central Pocket.

Max Planck Institute of Molecular Physiology
2
Antiproliferative and Antimigratory Effects of a Novel YAP-TEAD Interaction Inhibitor Identified Using in Silico Molecular Docking.

University of Bristol
23
Structure-Based Design and Synthesis of Potent Cyclic Peptides Inhibiting the YAP-TEAD Protein-Protein Interaction.

Roche Innovation Center Shanghai
3
Targeting Transcriptional Enhanced Associate Domains (TEADs).

Universities of Lille
154
COMPOUND ACTIVE AS INHIBITOR OF COLONY STIMULATION FACTOR-1 RECEPTOR (CSF-1 R)

Norwegian University of Science and Technology
317
PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN

Novartis
9
UNIT DOSAGE COMPOSITION OF AKT INHIBITOR

Nanjing Chia Tai Tianqing Pharmaceutical
12
Tricyclic amine compounds as CDK2 inhibitors

Incyte